welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
UK patients gain early access to Duchenne drug
UK patients can gain access to Santhera’s as-yet unapproved Duchenne muscular dystrophy drug via an early access scheme.
The Medicines and Healthcare products Regulatory Agency granted Raxone (idebenone) a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).
As a result of the decision, patients aged 10 and above with respiratory function decline, who are not taking gluticorticoids, will be able to get access to Raxone ahead of formal approval by the European Medicines Agency.
rareRelated
-
Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and ...Santhera Pharmaceuticals announces the d...
-
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)The primary objective of this Expanded A...
-
Santhera Completes Enrollment of Phase 3 SIDEROS Study With Puldysa® (Idebenone) in Duchenne Muscular Dystrophy (DM...Santhera Pharmaceuticals announces full ...
-
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in D...Santhera Pharmaceuticals announces that ...
-
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocortico...The purpose of the study is to assess th...
-
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophyIn Duchenne muscular dystrophy (DMD), pr...
-
Santhera Pharmaceuticals – LinkedInSanthera Pharmaceuticals (SIX: SANN) is ...
